Glucagon-like Peptide-1 Receptor in the Human Hypothalamus Is Associated with Body Mass Index and Colocalizes with the Anorexigenic Neuropeptide Nucleobindin-2/Nesfatin-1
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Data on animals emphasize the importance of the neuronal glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) for feeding suppression, although it is unclear whether astrocytes participate in the transduction of anorectic GLP-1R-dependent signals. In humans, the brain circuitry underlying these effects remains insufficiently investigated. The present study aimed to explore GLP-1R protein expression in the human hypothalamus and its correlation with body mass index (BMI). Sections of hypothalamus from 28 autopsy cases, 11 with normal weight (BMI < 25 kg/m2) and 17 with non-normal weight (BMI ≥ 25 kg/m2), were examined using immunohistochemistry and double immunofluorescence labeling. Prominent GLP-1R immunoexpression was detected in neurons of several hypothalamic nuclei, including paraventricular, supraoptic, and infundibular nuclei; the lateral hypothalamic area (LH); and basal forebrain nuclei. Interestingly, in the LH, GLP-1R was significantly decreased in individuals with BMI ≥ 25 kg/m2 compared with their normal weight counterparts (p = 0.03). Furthermore, GLP-1R was negatively correlated (τb = −0.347, p = 0.024) with BMI levels only in the LH. GLP-1R extensively colocalized with the anorexigenic and antiobesogenic neuropeptide nucleobindin-2/nesfatin-1 but not with the astrocytic marker glial fibrillary acidic protein. These data suggest a potential role for GLP-1R in the regulation of energy balance in the human hypothalamus. In the LH, an appetite- and reward-related brain region, reduced GLP-1R immunoexpression may contribute to the dysregulation of homeostatic and/or hedonic feeding behavior. Possible effects of NUCB2/nesfatin-1 on central GLP-1R signaling require further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1Rs in the DMH of humans were apparent (Fig. 1G and fig. S1F), consistent with prior findings (18).”
From GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Identification of nesfatin-1 as a satiety molecule in the hypothalamus
Oh-I, S., Shimizu, H., Satoh, T., Okada, S., Adachi, S., Inoue, K., Eguchi, H., Yamamoto, M., Imaki, T., Hashimoto, K., et al. (2006) · Nature · doi:10.1038/nature05162 · Cited by 1,009 · cited 1×
“Interestingly, nesfatin-1, an 82-amino acid peptide, derived from the 103 precursor nucleobindin-2 (NUCB2), is highly expressed both in human and rodent 104 hypothalamus and exerts pleiotropic actions including an inhibitory effect on food intake 105 and on body weight gain [13-16].”
BackgroundLebow, M. A., & Chen, A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.1 · Cited by 660 · cited 1×
“GLP-1R immunoreactivity was also detected in the medial preoptic area, 325 suprachiasmatic nucleus, mammillary nucleus, and bed nucleus of the stria terminalis, 326 which participate in food intake modulation in response to temperature change, 327 biological rhythms, memory, and emotional and behavioral responses to s…”
BackgroundSpotlight on protein N-terminal acetylation
Ree, R., Varland, S., & Arnesen, T. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0116-z · Cited by 646
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“The incretin hormone glucagon-like peptide-1 (GLP-1) is secreted from intestinal enteroendocrine L cells in response to nutrient ingestion and potentiates insulin release, suppresses glucagon secretion, delays gastric emptying, increases satiety, and reduces appetite and body weight [1].”
BackgroundLateral hypothalamic circuits for feeding and reward
Stuber, G. D., & Wise, R. A. (2016) · Nature Neuroscience · doi:10.1038/nn.4220 · Cited by 516 · cited 1×
“As one of the most extensively interconnected brain areas, the LH is involved in different aspects of food consumption, including hedonic feeding and body weight regulation [36,37].”
BackgroundCork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478 · cited 1×
“312 313 GLP-1R localization, as described herein, is similar with previous studies in humans and 314 animals [3-5, 10, 27-34].”
ResultGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“312 313 GLP-1R localization, as described herein, is similar with previous studies in humans and 314 animals [3-5, 10, 27-34].”
ResultRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427 · cited 2×
“GLP-1 and NUCB2/nesfatin-1 share similar physiologic properties in energy homeostasis and body weight [2,11,15,31].”
BackgroundArendt, T., Bigl, V., Tennstedt, A., & Arendt, A. (1985) · Neuroscience · doi:10.1016/0306-4522(85)90160-5 · Cited by 410 · cited 1×
“Experimental models and preclinical studies show beneficial effects of 382 GLP-1R agonism on Alzheimer’s disease neuropathological features, including 383 cholinergic basal forebrain nuclei degeneration, and on cognition [42-44].”
BackgroundThe lateral hypothalamic area revisited: Ingestive behavior
Bernardis, L. L., & Bellinger, L. L. (1996) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00015-1 · Cited by 402 · cited 1×
“As one of the most 335 extensively interconnected brain areas, LH is involved in different aspects of food 336 consumption, including hedonic feeding, and in body weight regulation [39, 40].”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312 · cited 2×
“312 313 GLP-1R localization, as described herein, is similar with previous studies in humans and 314 animals [3-5, 10, 27-34].”
BackgroundResultAlvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., García‐Cuartero, B., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., De Cáceres, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 305 · cited 2×
“312 313 GLP-1R localization, as described herein, is similar with previous studies in humans and 314 animals [3-5, 10, 27-34].”
MethodResultFarr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3874-y · Cited by 287 · cited 3×
“GLP-1R has been localized in the human hypothalamus using in situ hybridization techniques [3,4] and immunohistochemistry [5].”
BackgroundMethodResultInfluentialThe mammillary bodies: two memory systems in one?
Vann, S. D., & Aggleton, J. P. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1299 · Cited by 286 · cited 1×
“GLP-1R immunoreactivity was also detected in the medial preoptic area, 325 suprachiasmatic nucleus, mammillary nucleus, and bed nucleus of the stria terminalis, 326 which participate in food intake modulation in response to temperature change, 327 biological rhythms, memory, and emotional and behavioral responses to s…”
BackgroundSalcedo, I., Tweedie, D., Li, Y., & Greig, N. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01971.x · Cited by 259 · cited 1×
“Experimental models and preclinical studies show beneficial effects of 382 GLP-1R agonism on Alzheimer’s disease neuropathological features, including 383 cholinergic basal forebrain nuclei degeneration, and on cognition [42-44].”
BackgroundRole of orexin in modulating arousal, feeding, and motivation
Tsujino, N., & Sakurai, T. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00028 · Cited by 255 · cited 1×
“GLP-1R immunoreactivity was also detected in the medial preoptic area, 325 suprachiasmatic nucleus, mammillary nucleus, and bed nucleus of the stria terminalis, 326 which participate in food intake modulation in response to temperature change, 327 biological rhythms, memory, and emotional and behavioral responses to s…”
BackgroundBrown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222 · cited 1×
“Given the increasing evidence that brain circuits regulate energy homeostasis and body weight, the widespread use of GLP-1-based therapies for obesity and type 2 diabetes treatment [2] and the variable response of patients to these therapies [22], further studying of GLP-1R levels variations in key cell subpopulations…”
BackgroundZhou, D., Chen, Y.-W., Zhao, Z.-H., Yang, R.-X., Xin, F.-Z., Liu, X.-L., Pan, Q., Zhou, H., & Fan, J.-G. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0183-1 · Cited by 217 · cited 2×
“Specificity of GLP-1R 152 antiserum has been previously described in detail [21-23].”
MethodGlucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207
Heppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183 · cited 1×
“Furthermore, it has been 99 suggested that vagal afferents are involved in mediating the effects of GLP-1 on food 100 intake [12].”
BackgroundGlucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus
Shughrue, P. J. (1996) · Endocrinology · doi:10.1210/en.137.11.5159 · Cited by 182
Timper, K., del Río-Martín, A., Cremer, A. L., Bremser, S., Alber, J., Giavalisco, P., Varela, L., Heilinger, C., Nolte, H., Trifunovic, A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.001 · Cited by 170 · cited 2×
“Specificity of GLP-1R 152 antiserum has been previously described in detail [21-23].”
MethodNesfatin-1: functions and physiology of a novel regulatory peptide
Dore, R., Levata, L., Lehnert, H., & Schulz, C. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0361 · Cited by 167 · cited 2×
“homeostasis and body weight [2, 11, 15, 34], the aforementioned data, taken together 365 with our observations, may be indicative of GLP-1 and nesfatin-1 possible interactions in 366 the human hypothalamus.”
BackgroundSchick, R. R., Zimmermann, J. P., Walde, T. V., & Schusdziarra, V. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00479.2002 · Cited by 152
Jensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145
Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136
Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance
Reiner, D. J., Mietlicki-Baase, E. G., McGrath, L. E., Zimmer, D. J., Bence, K. K., Sousa, G. L., Konanur, V. R., Krawczyk, J., Burk, D. H., Kanoski, S. E., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3579-15.2016 · Cited by 133 · cited 1×
“The astrocytes that represent an important central nervous system cell population have been proposed to contribute to the transduction of anorectic GLP-1R-dependent signals in rats [6].”
BackgroundNeural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
Katsurada, K., & Yada, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12464 · Cited by 119 · cited 2×
“Nesfatin-1 neurons have been shown to contribute to 106 the anorexigenic effects of GLP-1 in an animal model of GLP-1R-mediated feeding 107 suppression [17, 18].”
BackgroundKatsurada, K., Maejima, Y., Nakata, M., Kodaira, M., Suyama, S., Iwasaki, Y., Kario, K., & Yada, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.116 · Cited by 112 · cited 2×
“Nesfatin-1 neurons have been shown to contribute to 106 the anorexigenic effects of GLP-1 in an animal model of GLP-1R-mediated feeding 107 suppression [17, 18].”
BackgroundNesfatin‐1: a novel inhibitory regulator of food intake and body weight
Stengel, A., Goebel, M., & Taché, Y. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00770.x · Cited by 98 · cited 1×
“Interestingly, nesfatin-1, an 82-amino acid peptide, derived from the 103 precursor nucleobindin-2 (NUCB2), is highly expressed both in human and rodent 104 hypothalamus and exerts pleiotropic actions including an inhibitory effect on food intake 105 and on body weight gain [13-16].”
BackgroundA novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Graham, D. L., Durai, H. H., Trammell, T. S., Noble, B. L., Mortlock, D. P., Galli, A., & Stanwood, G. D. (2020) · Journal of Comparative Neurology · doi:10.1002/cne.24905 · Cited by 88 · cited 2×
“312 313 GLP-1R localization, as described herein, is similar with previous studies in humans and 314 animals [3-5, 10, 27-34].”
BackgroundResultWu, Y., Eghbali, M., Ou, J. W., Lü, R., Toro, L., & Stefani, E. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.10.037 · Cited by 72 · cited 1×
“The possibility of a protein-to-protein physical interaction cannot be claimed based on colocalization [39]; thus, possible effects of NUCB2/nesfatin-1 on central GLP-1R signaling require further investigation.”
BackgroundChowen, J. A., de Fonseca, F. R., Álvarez, E., Navarro, M. A., García‐Segura, L. M., & Blázquez, E. (1999) · Neuropeptides · doi:10.1054/npep.1999.0757 · Cited by 70
Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
ten Kulve, J. S., van Bloemendaal, L., Balesar, R., IJzerman, R. G., Swaab, D. F., Diamant, M., la Fleur, S. E., & Alkemade, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3291 · Cited by 54 · cited 8×
“GLP-1R has been localized in human hypothalamus, using in situ hybridization 81 techniques [3, 4] and immunohistochemistry [5].”
BackgroundMethodResultInfluentialThe Hypothalamic Preoptic Area and Body Weight Control
Yu, S., François, M., Huesing, C., & Münzberg, H. (2017) · Neuroendocrinology · doi:10.1159/000479875 · Cited by 53 · cited 1×
“GLP-1R immunoreactivity was also detected in the medial preoptic area, 325 suprachiasmatic nucleus, mammillary nucleus, and bed nucleus of the stria terminalis, 326 which participate in food intake modulation in response to temperature change, 327 biological rhythms, memory, and emotional and behavioral responses to s…”
BackgroundRocha‐Ferreira, E., Poupon-Bejuit, L., Zelco, A., Leverin, A., Nair, S., Jonsdotter, A., Carlsson, Y., Thornton, C., Hagberg, H., & Rahim, A. A. (2018) · Brain · doi:10.1093/brain/awy220 · Cited by 51 · cited 2×
“Specificity of GLP-1R 152 antiserum has been previously described in detail [21-23].”
MethodRole of liraglutide in Alzheimer’s disease pathology
Vargas-Soria, M., Carranza-Naval, M. J., del Marco, A., & Garcia-Alloza, M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00853-0 · Cited by 44
Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong, D., Xie, J., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00407-3 · Cited by 38 · cited 1×
“Recent reports 384 suggest that brain-gut peptides, including GLP-1 and nesfatin-1, share neuroprotective 385 properties and might have therapeutic potential for neurodegenerative disorders [45-47].”
BackgroundXing, L., McDonald, H., Fonte, D. F. D., Gutierrez-Villagomez, J. M., & Trudeau, V. L. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00310 · Cited by 35 · cited 1×
“Specificity of antibodies used for 191 colocalization studies was previously published [16, 21-23, 25].”
MethodPsilopanagioti, A., Nikou, S., & Papadaki, H. H. (2019) · Neuroendocrinology · doi:10.1159/000496731 · Cited by 28 · cited 3×
“Interestingly, nesfatin-1, an 82-amino acid peptide, derived from the 103 precursor nucleobindin-2 (NUCB2), is highly expressed both in human and rodent 104 hypothalamus and exerts pleiotropic actions including an inhibitory effect on food intake 105 and on body weight gain [13-16].”
BackgroundMethodSelf-citationSingle-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes
Tschöp, M., & DiMarchi, R. (2017) · Diabetes · doi:10.2337/dbi16-0068 · Cited by 27 · cited 1×
“The essential molecular mechanisms underlying body weight gain remain largely unknown [46].”
BackgroundNucleobindin-2/Nesfatin-1—A New Cancer Related Molecule?
Kmiecik, A. M., Dzięgiel, P., & Podhorska‐Okołów, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158313 · Cited by 26 · cited 1×
“NUCB2/nesfatin-1 has also been proposed to play a role in cancer progression by enhancing proliferation, migration, invasion, and evasion of apoptosis in most cancer types although few studies report that NUCB2/nesfatin-1 inhibits cell proliferation and increases apoptosis [18].”
BackgroundSaito, R., So, M., Motojima, Y., Matsuura, T., Yoshimura, M., Hashimoto, H., Yamamoto, Y., Kusuhara, K., & Ueta, Y. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12400 · Cited by 22 · cited 2×
“In addition, intraperitoneal administration of GLP-1 has been 360 described to significantly increase activated nesfatin-1 neurons in hypothalamic nuclei, 361 while GLP‐1-induced food intake reduction has been significantly attenuated by 362 pretreatment with intracerebroventricular administration of antisense nesfati…”
BackgroundBułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., & Okopień, B. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7245 · Cited by 21 · cited 2×
“GLP-1R expression in astrocytes has been described within rat brain [6-8] and 93 in a human astrocyte cell line [9].”
BackgroundTamer, S. A., Koyuncuoğlu, T., Köroğlu, A. K., Akakın, D., Yüksel, M., & Yeğen, B. Ç. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120376 · Cited by 20
Minireview: Peripheral Nesfatin-1 in Regulation of the Gut Activity—15 Years since the Discovery
Kras, K., Muszyński, S., Tomaszewska, E., & Arciszewski, M. B. (2022) · Animals · doi:10.3390/ani12010101 · Cited by 17
GLP-1 Based Combination Therapy for Obesity and Diabetes
Lee, Y. H., Lee, H. W., & Choi, H. J. (2017) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2017.26.3.155 · Cited by 12 · cited 1×
“In our research, important biological information into the chemical neuroanatomy of the normal weight human hypothalamus and the hypothalamus affected by excess adiposity may be derived, providing an opportunity to gain insight into the mechanism underlying the considerable variation in achieving significant weight re…”
BackgroundPsilopanagioti, A., Makrygianni, M., Nikou, S., Logotheti, S., & Papadaki, H. H. (2020) · Journal of Neuroendocrinology · doi:10.1111/jne.12899 · Cited by 8 · cited 1×
“147 Immunohistochemistry was performed as previously described [16, 20].”
MethodSelf-citationMerchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5 · cited 1×
“312 313 GLP-1R localization, as described herein, is similar with previous studies in humans and 314 animals [3-5, 10, 27-34].”
Result
Research works printed but not linked: 2
- Swaab D.F. Part I: Nuclei of the human hypothalamus: Cytoarchitecture, chemoarchitecture, functional neuroanatomy, topographic neuropathology Handbook of Clinical Neurology. The Human Hypothalamus: Basic and Clinical Aspects Aminoff M.J. Boller F. Swaab D.F. Elsevier Amsterdam, The Netherlands 2003 Volume 79 3 59
- Mai J. Majtanik M. Paxinos G. Part 2: Myelo- and cytoarchitectonic atlas of the human brain in stereotaxic (MNI) space Atlas of the Human Brain 4th ed. Mai J. Majtanik M. Paxinos G. Academic Press Cambridge, MA, USA Elsevier Amsterdam, The Netherlands 2015 181–233, 427–431
Cited by
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kim, K. S., Park, J. S., Hwang, E., Park, M. J., Shin, H. Y., Lee, Y. H., Kim, K. M., Gautron, L., Godschall, E., Portillo, B., et al. (2024) · Science · doi:10.1126/science.adj2537 · Cited by 148
Krajewski, P. K., Złotowska, A., & Szepietowski, J. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216292 · Cited by 84
“Beyond metabolic benefits, GLP-1 RAs exhibit cardioprotective effects, reducing the risk of cardiovascular events such as stroke and myocardial infarction [53].”
BackgroundInfluentialA comprehensive review of genetic causes of obesity
Concepción‐Zavaleta, M. J., Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., de la Cruz, J. D. C. V., Barrueto-Callirgos, C. M., Puelles‐León, S. L., Alvarado-León, E. D. J., Cabrera, F. A. L., Zavaleta‐Gutiérrez, F. E., et al. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00757-z · Cited by 28
“Gut hormones cholecystokinin, peptide YY, pancreatic polypeptide, glucagon-like peptide 1 (GLP-1), nesfatin 1, oxyntomodulin, and uroguanylin mediate satiety signals in the paraventricular nucleus of the hypothalamus in addition to the stimulation of insulin production [26–28].”
GLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“A cadaveric study found a decrease in GLP-1R expression in the LH that correlated with increased BMI, suggesting that reduced GLP-1R signaling in the LH may contribute to dysregulated feeding behavior in individuals with obesity [127].”
Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy
Barnwal, N., Dubey, S., & Tiwari, P. K. (2025) · Current Drug Metabolism · doi:10.2174/0113892002408089250912080734 · Cited by 190
Metadata
- Authors
- Psilopanagioti, A., Nikou, S., Logotheti, S., Arbi, M., Chartoumpekis, D. V., & Papadaki, H.
- Affiliations
- University of Patras (GR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Psilopanagioti, Aristea
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-28
- Volume
- 23
- Issue
- 23
- Pages
- 14899
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9740138
- OpenAlex
- W4310154266
- Cited by
- 22
- References
- 52
- Citations by year
- 2026: 10 · 2025: 4 · 2024: 6 · 2023: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Patras
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- GLP-1 receptor, hypothalamus, NUCB2, nesfatin-1, lateral hypothalamus, body mass index, obesity, energy balance, appetite regulation, feeding behavior, neuropeptide co-localization, astrocytes, glial fibrillary acidic protein
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Arcuate Nucleus of Hypothalamus, Humans, Hypothalamus, Neuropeptides, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.